Last Updated : July 28, 2024
The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Gazyva | Obinutuzumab | Follicular Lymphoma | Reimburse with clinical criteria and/or conditions | Complete | ||
Gazyva | Obinutuzumab | Follicular Lymphoma (previously untreated) | Do not reimburse | Complete | ||
Gazyva | Obinutuzumab | Chronic Lymphocytic Leukemia | Reimburse | Complete | ||
Gelnique | Oxybutynin Chloride Gel | Overactive bladder | Do not list | Complete | ||
Genotropin | Somatropin | Growth hormone deficiency, adult | List with criteria/condition | Complete | ||
Genotropin | Somatropin | Growth hormone deficiency, children | List with criteria/condition | Complete | ||
Genotropin | Somatropin | Turner Syndrome | List with criteria/condition | Complete | ||
Genvoya | Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide | HIV infection | List | Complete | ||
Gilenya | Fingolimod | Multiple Sclerosis, relapsing-remitting | List with clinical criteria and/or conditions | Complete | ||
Giotrif | Afatinib | Advanced or Metastatic Non-Small Cell Lung Cancer | Reimburse | Complete |